Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 85-92

  Reid, A L ^a   Millward, M ^b   Pearce, R ^a   Lee, M ^b   Frank, M H ^c   Ireland, A ^b   Monshizadeh, L ^b   Rai, T ^a   Heenan, P ^b   Medic, S ^a   Kumarasinghe, P ^d   Ziman, Melanie ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d St John of God Subiaco Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B5; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD146 ANTIGEN; MELAN A; RECOMBINANT ALPHA2B INTERFERON; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX3D; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MULTICENTER STUDY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOFREQUENCY ABLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SKIN SURGERY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872840013     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12057     Document Type: Article

References (46)

1. Tucker MA,. Melanoma Epidemiology. Hematol Oncol Clin North Am 2009; 23: 383-95.
2. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
3. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
4. Pollack AL, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol 2011; 65: S78-86.
5. Tsao H, Cosimi AB, Sober AJ,. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997; 79: 2361-70.
6. Shen P, Guenther JM, Wanek LA, Morton DL,. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol 2000; 7: 114-19.
7. Stoecklein N, Hosch S, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 13: 441-53.
8. Sastre J, Maestro ML, Puente J, et al. Circulating tumour cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008; 19: 935-8.
9. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003; 107: 984-90.
10. Shariat SF, Kattan MW, Song W, et al. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res 2003; 63: 5874-8.
11. Müller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11: 3678-85.
12. Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94: 672-80.
13. Lembessis P, Msaouel P, Halapas A, et al. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med 2007; 45: 1488-94.
14. Pfitzenmaier J, Ellis WJ, Hawley S, et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007; 25: 214-20.
15. Wong SC, Chan CM, Ma BB, et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009; 15: 1005-12.
16. Allen JE, El-Deiry WS,. Circulating tumor cells and colorectal cancer. Curr Colorectal Cancer Rep 2010; 6: 212-20.
17. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-9.
18. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-16.
19. Brownbridge GG, Gold J, Edward M, MacKie RM,. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001; 144: 279-87.
20. Reynolds SR, Albrecht J, Shapiro RL, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9: 1497-502.
21. Gkalpakiotis S, Arenberger P, Kremen J, Arenbergerova M,. Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5 years study. Exp Dermatol 2010; 19: 994-9.
22. Rao C, Bui T, Connelly M, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 2011; 38: 755-60.
23. Ma J, Frank MH,. Tumor initiation in human malignant melanoma and potential cancer therapies. Anticancer Agents Med Chem 2010; 10: 131-6.
24. Schatton T, Frank MH,. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 2009; 1176: 154-69.
25. Koyanagi K, Kuo C, Nakagawa T, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005; 51: 981-8.
26. Parker KA, Glaysher S, Polak M, et al. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 2010; 63: 1012-20.
27. Vachtenheim J, Novotná H,. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol Biol 1999; 45: 1075-82.
28. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
29. Kokkinakis DM, Liu X, Chada S, et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 2004; 64: 7513-25.
30. Bardin N, Francès V, Lesaule G, et al. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 1996; 218: 210-16.
31. Frank NY, Pendse SS, Lapchak PH, et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003; 278: 47156-65.
32. Medic S, Rizos H, Ziman M,. Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochem Biophys Res Commun 2011; 411: 832-7.
33. Medic S, Ziman M,. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol 2009; 44: 85-97.
34. Medic S, Ziman M,. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas). PLoS ONE 2010; 5: e9977.
35. Matsuzaki Y, Hashimoto S, Fujita T, et al. Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). J Immunother 2005; 28: 10-19.
36. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
37. Koyanagi K, O'Day SJ, Boasberg P, et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010; 16: 2402-8.
38. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002; 48: 1883-90.
39. Longo MC, Berninger MS, Hartley JL,. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990; 93: 125-8.
40. Giricz O, Lauer-Fields JL, Fields GB,. The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Anal Biochem 2008; 380: 137-9.
41. Tautz D, Renz M,. An optimized freeze-squeeze method for the recovery of DNA fragments from agarose gels. Anal Biochem 1983; 132: 14-19.
42. Curry BJ, Myers K, Hersey P,. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16: 1760-9.
43. Hoek K, Eichhoff O, Schlegel N, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68: 650-6.
44. Hüsemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
45. Aubin F, Chtourou M, Teyssier JR, et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 2000; 10: 113-18.
46. Luca M, Hunt B, Bucana CD, et al. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993; 3: 35-41.